Ultra-Sensitive Tumor-Informed ctDNA Monitoring of Molecular Residual Disease (MRD) & Response to Immunotherapy in the Advanced Disease Setting
Time: 2:10 pm
day: Day 2 Track A PM
Details:
- Ultra-sensitive ctDNA assays are required for accurate classification of patient MRD status and treatment monitoring
- Low ctDNA levels are commonly observed, even in late stage disease, with positive ctDNA detections in these studies occurring as low as 2.3 PPM
- Detections down to low PPM levels correlate strongly with RECIST-derived classifications of response
